RJA
TAK icon

Raymond James & Associates’s Takeda Pharmaceutical TAK Stock Holding History

Raymond James & Associates’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.75M Sell
193,566
-62,196
-24% -$882K ﹤0.01% 2024
2024
Q2 		$3.31M Buy
255,762
+12,862
+5% +$170K ﹤0.01% 1863
2024
Q1 		$3.37M Buy
242,900
+20,531
+9% +$299K ﹤0.01% 1838
2023
Q4 		$3.17M Buy
222,369
+57,134
+35% +$811K ﹤0.01% 1816
2023
Q3 		$2.56M Sell
165,235
-6,750
-4% -$104K ﹤0.01% 1864
2023
Q2 		$2.7M Buy
171,985
+29,420
+21% +$482K ﹤0.01% 1877
2023
Q1 		$2.35M Buy
142,565
+14,761
+12% +$235K ﹤0.01% 1936
2022
Q4 		$1.99M Buy
127,804
+24,949
+24% +$348K ﹤0.01% 1989
2022
Q3 		$1.33M Sell
102,855
-9,933
-9% -$138K ﹤0.01% 2224
2022
Q2 		$1.58M Sell
112,788
-19,438
-15% -$277K ﹤0.01% 2152
2022
Q1 		$1.89M Buy
132,226
+29,087
+28% +$427K ﹤0.01% 2168
2021
Q4 		$1.41M Sell
103,139
-122,402
-54% -$1.72M ﹤0.01% 2411
2021
Q3 		$3.69M Sell
225,541
-17,631
-7% -$296K ﹤0.01% 1698
2021
Q2 		$4.09M Buy
243,172
+16,540
+7% +$282K ﹤0.01% 1622
2021
Q1 		$4.14M Sell
226,632
-783,817
-78% -$14.1M ﹤0.01% 1555
2020
Q4 		$18.4M Sell
1,010,449
-80,564
-7% -$1.41M 0.02% 659
2020
Q3 		$19.5M Sell
1,091,013
-73,894
-6% -$1.35M 0.02% 550
2020
Q2 		$20.9M Sell
1,164,907
-47,324
-4% -$850K 0.03% 501
2020
Q1 		$18.4M Buy
1,212,231
+174,691
+17% +$3.17M 0.03% 483
2019
Q4 		$20.5M Buy
1,037,540
+85,410
+9% +$1.63M 0.03% 571
2019
Q3 		$16.4M Buy
952,130
+263,461
+38% +$4.56M 0.02% 638
2019
Q2 		$12.2M Buy
688,669
+186,425
+37% +$3.39M 0.02% 757
2019
Q1 		$10.2M Buy
502,244
+459,051
+1,063% +$9.24M 0.02% 816
2018
Q4 		$727K Buy
+43,193
New +$729K ﹤0.01% 2291

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Raymond James & Associates's TAK Position: Q3 2024 in Review

Raymond James & Associates reduced its Takeda Pharmaceutical (TAK) stake by 24% in Q3 2024, selling an estimated $882K and leaving 193,566 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

Raymond James & Associates first reported a position in TAK in Q4 2018 and has held it in 24 quarters since. The position peaked at $20.9M in Q2 2020. 298 funds tracked by Wall St. Rank hold TAK as of Q3 2024.

  • Raymond James & Associates held 193,566 shares of Takeda Pharmaceutical worth $2.75M as of Q3 2024.
  • Raymond James & Associates sold 62,196 Takeda Pharmaceutical shares in Q3 2024, an estimated $882K.
  • Takeda Pharmaceutical made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2024 holding.
  • Raymond James & Associates first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 24 quarters since.
  • Raymond James & Associates's Takeda Pharmaceutical position peaked at $20.9M in Q2 2020.
  • 298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.